$SCYX News

SCYNEXIS Completes Phase 1 Study of Intravenous SCY-247, a Novel, Triterpenoid Antifungal in Development for Treatment and Prevention of Invasive Fungal Diseases

SCYNEXIS Announces Its Phase 1 Trial Of Intravenous Formulation Of SCY-247 To Treat Invasive Fungal Infections Showed Intravenous Doses Of 50 Mg Or Higher Achieved Exposures At Or Above Target Identified In Murine Models Of Invasive Candidiasis

SCYNEXIS to Feature SCY-247 in a Pipeline Presentation at IDWeek

SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

SCYNEXIS Completes Phase 1 Study Of SCY-770, Selective And Direct AMP-Activated Protein Kinase Activator

Scynexis stock surges on $214M BARDA contract for SCY-247

Scynexis Shares Rise 13.9% After BARDA Awards SCY-247 Development Contract

SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247

SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer

SCYNEXIS Appoints Sanjay Subramanian As CFO, Effective September 9

SCYNEXIS to Participate in Upcoming Investor Conferences

SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Guggenheim Maintains Buy on SCYNEXIS, Raises Price Target to $33

SCYNEXIS Reports Second Quarter 2026 Financial Results and Provides Corporate Update

UPDATE: SCYNEXIS Q2 Adj. EPS $(0.57) Misses $(0.51) Estimate, Sales $235.000K Beat $80.330K Estimate

SCYNEXIS Q2 EPS $0.63 Beats $(0.64) Estimate, Sales $235.000K Beat $80.330K Estimate

SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

SCYNEXIS Starts Phase 1 Trial Of SCY-770 Activator Of Two Dosing Regimens

SCYNEXIS Announces One-for-Eight Reverse Stock Split

SCYNEXIS Announces 1-For-8 Reverse Stock Split, Effective May 29